SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

被引:355
|
作者
Corbett, Kizzmekia S. [1 ]
Edwards, Darin K. [2 ]
Leist, Sarah R. [3 ]
Abiona, Olubukola M. [1 ]
Boyoglu-Barnum, Seyhan [1 ]
Gillespie, Rebecca A. [1 ]
Himansu, Sunny [2 ]
Schafer, Alexandra [3 ]
Ziwawo, Cynthia T. [1 ]
DiPiazza, Anthony T. [1 ]
Dinnon, Kenneth H. [3 ]
Elbashir, Sayda M. [2 ]
Shaw, Christine A. [2 ]
Woods, Angela [2 ]
Fritch, Ethan J. [4 ]
Martinez, David R. [3 ]
Bock, Kevin W. [5 ]
Minai, Mahnaz [5 ]
Nagata, Bianca M. [5 ]
Hutchinson, Geoffrey B. [1 ]
Wu, Kai [2 ]
Henry, Carole [2 ]
Bahl, Kapil
Garcia-Dominguez, Dario [2 ]
Ma, LingZhi [2 ]
Renzi, Isabella [2 ]
Kong, Wing-Pui [1 ]
Schmidt, Stephen D. [1 ]
Wang, Lingshu [1 ]
Zhang, Yi [1 ]
Phung, Emily [1 ,6 ]
Chang, Lauren A. [1 ]
Loomis, Rebecca J. [1 ]
Altaras, Nedim Emil [2 ]
Narayanan, Elisabeth [2 ]
Metkar, Mihir [2 ]
Presnyak, Vlad [2 ]
Liu, Cuiping [1 ]
Louder, Mark K. [1 ]
Shi, Wei [1 ]
Leung, Kwanyee [1 ]
Yang, Eun Sung [1 ]
West, Ande [3 ]
Gully, Kendra L. [3 ]
Stevens, Laura J. [7 ]
Gully, Kendra L. [3 ]
Wang, Nianshuang [8 ]
Wrapp, Daniel [8 ]
Doria-Rose, Nicole A. [1 ]
Stewart-Jones, Guillaume [2 ]
机构
[1] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
[2] Moderna Inc, Cambridge, MA USA
[3] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27515 USA
[4] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27515 USA
[5] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
[6] George Washington Univ, Inst Biomed Sci, Washington, DC USA
[7] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA
[8] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA
[9] NIAID, Biostat Res Branch, Div Clin Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
关键词
MERS-COV; SPIKE; INFLUENZA; IMMUNOGENICITY; PROTECTION; VIRUS; RSV;
D O I
10.1038/s41586-020-2622-0
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have led to the development of mutations that stabilize Betacoronavirus spike proteins in the prefusion state, improving their expression and increasing immunogenicity(1). This principle has been applied to design mRNA-1273, an mRNA vaccine that encodes a SARS-CoV-2 spike protein that is stabilized in the prefusion conformation. Here we show that mRNA-1273 induces potent neutralizing antibody responses to both wild-type (D614) and D614G mutant(2) SARS-CoV-2 as well as CD8(+) T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a phase III trial to evaluate its efficacy.
引用
收藏
页码:567 / +
页数:21
相关论文
共 50 条
  • [31] Serological response to a single dose of a SARS-CoV-2 mRNA vaccine
    Ramos, Angelica
    Cardoso, Maria Joao
    Norton, Pedro
    Sarmento, Antonio
    Guimaraes, Joao Tiago
    JOURNAL OF VIROLOGICAL METHODS, 2021, 296
  • [32] Predicting the protective humoral response to a SARS-CoV-2 mRNA vaccine
    Meschi, Silvia
    Matusali, Giulia
    Colavita, Francesca
    Lapa, Daniele
    Bordi, Licia
    Puro, Vincenzo
    Leoni, Bruno D.
    Galli, Claudio
    Capobianchi, Maria Rosaria
    Castilletti, Concetta
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (12) : 2010 - 2018
  • [33] Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
    Ali, Kashif
    Berman, Gary
    Zhou, Honghong
    Deng, Weiping
    Faughnan, Veronica
    Coronado-Voges, Maria
    Ding, Baoyu
    Dooley, Jacqueline
    Girard, Bethany
    Hillebrand, William
    Pajon, Rolando
    Miller, Jacqueline M.
    Leav, Brett
    McPhee, Roderick
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24): : 2241 - 2251
  • [34] Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting
    Townsend, Jeffrey P.
    Hassler, Hayley B.
    Dornburg, Alex
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (02)
  • [35] SARS-COV-2 MRNA vaccine-associated cutaneous vasculitis
    Erol, Vedat Bugra
    Can, Meryem
    NORTHERN CLINICS OF ISTANBUL, 2023, 10 (06) : 816 - 818
  • [36] Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals
    Grunau, Brian
    Goldfarb, DavidM.
    Asamoah-Boaheng, Michael
    Golding, Liam
    Kirkham, Tracy L.
    Demers, Paul A.
    Lavoie, Pascal M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (03): : 279 - 281
  • [37] Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine
    Marcelino, Joao
    Farinha, Sofia
    Silva, Rita
    Didenko, Irina
    Proenca, Miguel
    Tomaz, Elza
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (06): : 2476 - 2477
  • [38] A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine
    Young, J.
    Mercieca, L.
    Ceci, M.
    Pisani, D.
    Betts, A.
    Boffa, M. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (01) : 12 - E16
  • [39] Does the SARS-CoV-2 mRNA vaccine damage the ovarian reserve?
    Yildiz, Elif
    Timur, Burcu
    Guney, Gurhan
    Timur, Hakan
    MEDICINE, 2023, 102 (20) : E33824
  • [40] SARS-CoV-2 mRNA vaccine: Sometimes life needs a boost
    Lo, Carson Ka-Lok
    Kumar, Deepali
    TRANSPLANT INFECTIOUS DISEASE, 2023, 25 (05)